Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
Updated
Presolicitation from the National Institutes of Health, for work in Bethesda, Maryland. Due Nov 11, 2026, 4:00 PM (UTC-5), 4 days left.
| Solicitation number | NOI-27-000056 |
|---|---|
| Agency | National Institutes of Health |
| Office | National Institutes of Health - Cc |
| Notice type | Presolicitation |
| Set-aside | None |
| Trade (NAICS) | Pharmaceutical Preparation Manufacturing (325412) |
| Product or service code | 6505 |
| Place of performance | Bethesda, Maryland |
| Posted | Nov 6, 2026 |
| Response deadline | Nov 11, 2026, 4:00 PM (UTC-5) (4 days left) |
| Add the deadline to | Google Calendar · Apple / Outlook (.ics) |
Federal prevailing wage rates for this place: Maryland Davis-Bacon and SCA wage determinations.
Description
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements.
The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care.
The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year.
Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement.
For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485.
No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer.
Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements.
This is not a request for proposal. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: [email protected] All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Contracting contact
- Lu Chang · [email protected]
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
Is your business small enough?
For NAICS 325412, a business counts as small if it has no more than 1,300 employees (SBA size standard). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.
Companies that win this kind of work
Federal contractors paid for pharmaceutical preparation manufacturing work, who also hold NIH contracts (last 12 months): possible competitors, or partners to team with.
- DLA Troop Support $68.3 million in this trade
- Progenics Pharmaceuticals Inc $40.8 million in this trade
- Mriglobal $1.4 million in this trade
- Trillamed LLC $1.1 million in this trade
- Roche Diagnostics Corporation $631,652 in this trade
About the buyer
The National Institutes of Health awarded $5.9 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.
Pharmaceutical Preparation Manufacturing contracts right now
There are 23 open government contract opportunities in this trade (NAICS 325412), 11 posted in the last 7 days; 13% are set aside for small businesses. The agencies buying the most are Department of Veterans Affairs, Defense Logistics Agency and Department of State. Most of the work with a stated place is in Pennsylvania, Maryland and South Carolina. A notice in this trade gives a median of 13 days from posting to deadline; this one gives 5 days.
All open pharmaceutical preparation manufacturing contracts
Recent awards in this trade
- Denali Therapeutics Inc. $600,000 · Department of Veterans Affairs · Nov 4, 2026
- Novartis Pharmaceuticals Corporation $769,497 · Department of Veterans Affairs · Oct 29, 2026
- Nuclear Diagnostic Products Of Philadelphia, Inc $1.2 million · Department of Veterans Affairs · Oct 29, 2026
- Alembic Therapeutics LLC $475,000 · Department of Veterans Affairs · Oct 26, 2026
- Avkare LLC $1.6 million · Department of Veterans Affairs · Oct 23, 2026
From the award notices agencies publish.